In autumn and winter, respiratory viruses are menacing: influenza, mycoplasma pneumonia, respiratory syncytial virus infection and other respiratory infections are frequent, high fever and cough are frequent one after another, and the medical system is also overwhelmed. Industry experts have repeatedly called for prevention to be the first line of defense for respiratory infectious diseases, and safe and effective vaccines should become the first line of defense to protect the public. During the Spring Festival, family reunions and guests are full of guests, and while gathering to the fullest, we should also be vigilant against respiratory viruses to "join in the fun". The Infectious Disease Management Division of the Chinese Center for Disease Control and Prevention also advises the public to do a good job of self-health monitoring, maintain good hygiene habits, and get vaccinated against influenza and pneumonia in a timely manner to protect themselves and their relatives and friends.
Clover, which is committed to building a leading respiratory vaccine product portfolio, today launched the brand promotional video "Three Lives, All Things, All Things Breathe". The whole film takes "guarding the breath" as the main line, telling the story of Clover creatures, and sincerely telling the social responsibility of a local innovative enterprise. At the beginning of the new year, Clover would like to offer its blessings and continue to protect people's respiratory health with innovative vaccine products!
Clover's new brand trailer is a sneak peek:
From the beauty and preciousness of "one breath and one breath" to the suffocation and anxiety of "respiratory infectious diseases", "when the breath of life is threatened, who will protect the breath of all things?" Clover is deeply engaged in the field of respiratory vaccines, hoping to help the public build an immune barrier to respiratory diseases and protect the public with high-quality and safe vaccines.
Who is Shamrock?
Clover is committed to saving lives and improving global health through innovative vaccines, leveraging transformative science and global partnerships to bring innovative vaccines to the world and to more people. With combined R&D capabilities, manufacturing and commercialization capabilities, and strong partnerships with global organizations, Clover has developed a diverse pipeline of vaccine candidates that enable innovative vaccines to prevent more diseases and help reduce the burden on public health.
Innovation at the source
Clover is committed to source innovation and has a leading protein trimer-tag vaccine development platform, which is the only technology platform in the world that uses human trimerized tags for the production of recombinant, covalently linked antigens. Clover's technology platform has been fully validated with its first commercial vaccine product, and its applicability can be extended to other pipeline candidates. In addition, Clover has a proven global vaccine development capability spanning five continents (eight countries) and a global scientific advisory board with extensive expertise to energize the development of innovative in-house pipelines.
Global collaboration
Clover is actively exploring and collaborating globally with reputable partners; Earlier this year, it signed an exclusive agreement with Guoguang Biotechnology Co., Ltd. *** to distribute the quadrivalent influenza vaccine Adimflu-S (QIS) in Chinese mainland. Clover has also received a Coalition for Epidemic Preparedness Innovations (CEPI) 3$9.7 billion to support research and development of the COVID-19 vaccine, SCB-2019, among others. Clover is still actively exploring new strategic relationships with the world's top biopharmaceutical companies, biotechnology companies and academic institutions to help it pursue innovative vaccines.
Commercial production
Clover has a strong focus and established and growing commercial manufacturing capabilities. Clover's commercially-ready, commercial-ready facility in Changxing, Zhejiang Province has passed multiple GMP inspections in China and has been granted a Vaccine Drug Manufacturing License (DML) by the Zhejiang Provincial Drug Administration, preparing for the commercial production of its proprietary pipeline products. At the same time, Clover Biotech's own commercialization team has also entered into a strategic partnership with Keyuan** to leverage its extensive sales and distribution network to supplement its own commercialization capabilities.
Product pipeline
Clover has polished its resilience and focused on building a leading respiratory vaccine portfolio. It currently has two commercial-stage vaccine products (i.e., quadrivalent seasonal influenza vaccine and COVID-19 vaccine), and its in-house pipeline of respiratory syncytial virus (RSV) vaccine candidate SCB-1019 is gaining momentum. Clover has successfully developed a highly stable trimeric antigen that is close to the native sequence and natural pre-fusion F (pre-F) structure, and has applied for a patent. According to its recently published preclinical trial data, SCB-1019 has demonstrated higher neutralizing antibodies and higher quality antibody levels than the other two RSV vaccines that have been commercialized internationally. Thanks to its fully human trimer-tag vaccine technology platform and the experience of multiple clinical trials based on previous vaccine development, it is expected that there will be no pre-existing immunity, which has the potential to meet the vaccination needs of RSV vaccines requiring annual and seasonal booster vaccination. Clover's SCB-1019 will not be an oil-in-water emulsion adjuvant and may exhibit excellent safety and tolerability profiles. In the next step, Clover will accelerate the clinical application and development work, and look forward to the clinical progress of more RSV vaccine candidates in 2024.
Clover is committed to innovation at the source, focusing on respiratory vaccine products, and believes in the power of accumulation. As a local innovator, Clover is socially responsible and supports the health of China and the world with innovative vaccine products. In an interview, Mr. Liang Guo, CEO and Executive Director of Clover, said that innovative entrepreneurs are willing to use innovation to give back to society and protect the public. "Clover's insistence on source innovation is fundamentally based on my invention of the Trimer-Tag vaccine R&D platform, which is a technology that uses the body's natural protein trimer tag to secretively express disulfide covalently stable natural virus-like trimer-like antigens," explained Dr. Peng Liang, Founder, Chairman and Chief Scientific Officer of Clover. rabies virus, etc.) surface antigens are presented in the form of natural trimer structure, and the essence of trimer-tag technology comes from the most abundant collagen trimer structure in the human body, which can trimerize any target fusion protein, so as to obtain stable virus surface antigen with native trimer-like structure; Coupled with the good safety characteristics brought by humanization, the trimer-tag technology has strong versatility in the development of recombinant vaccines. Dr. Liang added, "In addition to our self-developed and commercialized COVID-19 vaccines, the prospect of the clinical-stage RSV vaccine, which is also based on the Trimer-Tag technology platform, is also optimistic about the industry. Dr. Liang's patient explanation could not hide his dedication to scientific exploration and his cherishing of hard-won research and development results, "At Clover, we have never stopped exploring research and development. ”
*:Xinhua.
Disclaimer: **This article is for the purpose of conveying more information and facilitating the popularization of law. If there is a ** marking error or infringement of your legitimate rights and interests, please contact Qinghai Law Popularization with the ownership certificate, and we will correct and delete it in time, thank you.